New VP of sales

[anonymous]

Lots of negative people in Vegas but not that many left. Relypsa and ZS didn't want you either?

 

[anonymous]

Poor hires across the board. Panels are a joke. Filling territories without a manger in place or territories alignment finalized? Very few with renal experience. Management is desperate to fill voids and will hire a monkey if necessary. Keryx will turn over more than 50% of original sales force by second quarter next year. No one has confidence leadership.

WOW. Managers, please do a better job of hiring this time around. Obviously, the panel interviews did not do a good job of filtering out this idiot or the rest of the whiny reps that are left. Most of the good ones have already quit. No one else wants the ones that we are stuck with.

 

[anonymous]

Sounds like a post from someone from the Yahoo board. Go back there you idiot.
Has Auryxia been shown to be superior to Renvela, Valphoro or even calcium. I think not. Until you have head to head studies, get your head out of the sand. This drug will do well in the future when it has the indication for IAD until then have fun

Why in the world do you need "head to head studies" of efficacy? Do you know the drug all but eliminates the need for IV iron? I know its not in the label blah blah blah blah, but the compound is called FERRIC CITRATE. Just say its name, it should be understood. for gawd sake.

 

[anonymous]

Why in the world do you need "head to head studies" of efficacy? Do you know the drug all but eliminates the need for IV iron? I know its not in the label blah blah blah blah, but the compound is called FERRIC CITRATE. Just say its name, it should be understood. for gawd sake.

Keryx can't even pay the bills. Reps not getting their AMEX paid. Sounds like trouble to me.

 

[anonymous]

didnt think it was possible but we are more demoralized after national call today than when we left vegas. will deal mean we will get reimbursed for amex? top talent not coming here. original hires looking to jump ship

 

[anonymous]

Why in the world do you need "head to head studies" of efficacy? Do you know the drug all but eliminates the need for IV iron? I know its not in the label blah blah blah blah, but the compound is called FERRIC CITRATE. Just say its name, it should be understood. for gawd sake.

That's it! Holy crap all we have to do is say ferric citrate!! Its a slam dunk! You are such a dick.

 

[anonymous]

The majority of field doesn't have faith in GM, AC, and think TC is a blowhard. GM lies like a rug. When the other nephrology start hiring we'll see how many stay.

didnt think it was possible but we are more demoralized after national call today than when we left vegas. will deal mean we will get reimbursed for amex? top talent not coming here. original hires looking to jump ship

 

[anonymous]

The saddest part of this is that the good reps will leave - The crappy reps who can't get hired elsewhere will stay.

 

[anonymous]

Please post the authors and the publications of the head to head studies with either Velphoro or Renvela showing superior efficacy for hyperphosphatemia. I believe that is the only indication right now for any of these......idiot

I don't even work for the company but I can tell you...

Auryxia ...

1. Is an effective phosphate binder

2. Increased ferritin (Renvela/Phoslo +2% … Auryxia + 51% (p=.0001))

3. Increased TSAT (Renvela/Phoslo -3% … Auryxia + 26% (p=.0001))

4. Lowers Iron-IVs (= $hundreds of millions saved / year)

5. Lowers ESA’s (= $hundreds of millions saved / year)

6. Causes higher hemoglobin (Renvela/Phoslo -0.6(g/dL … Auryxia +0.2 g/dL (p = .0105)

7. Causes lower FGF-23 (Placebo +11% … Auryxia -37% (p = .017)

8. Has fewer serious side effects

9. Results in 24% fewer hospitalizations (!) (= $thousands saved per member per year, not to mention what this means to patients)

10. Saves veins – “I think another important point for those patients with CKD who eventually progress is simply avoiding intravenous cannulations and hospitalizations and infusion center admissions are not only cost savings but they are vein savings. Meaning that avoiding intravenous therapy of any type is a priority for patients who are ultimately progressing toward end-stage renal disease care to preserve their veins for arteriovenous distally.” -- Dr. Glenn Chowtow - Chief, Division of Nephrology and Professor of Medicine at Stanford University School of Medicine, 11/5/13 conference call.

Need anymore info?

 

[anonymous]

Hello...There is NOTHING else the field can legally promote other than it's a phosphate binder of similar efficacy. There is a WARNING regarding the need to monitor iron stores to avoid iron overload.

 

[anonymous]

I don't even work for the company but I can tell you...

Auryxia ...

1. Is an effective phosphate binder

2. Increased ferritin (Renvela/Phoslo +2% … Auryxia + 51% (p=.0001))

3. Increased TSAT (Renvela/Phoslo -3% … Auryxia + 26% (p=.0001))

4. Lowers Iron-IVs (= $hundreds of millions saved / year)

5. Lowers ESA’s (= $hundreds of millions saved / year)

6. Causes higher hemoglobin (Renvela/Phoslo -0.6(g/dL … Auryxia +0.2 g/dL (p = .0105)

7. Causes lower FGF-23 (Placebo +11% … Auryxia -37% (p = .017)

8. Has fewer serious side effects

9. Results in 24% fewer hospitalizations (!) (= $thousands saved per member per year, not to mention what this means to patients)

10. Saves veins – “I think another important point for those patients with CKD who eventually progress is simply avoiding intravenous cannulations and hospitalizations and infusion center admissions are not only cost savings but they are vein savings. Meaning that avoiding intravenous therapy of any type is a priority for patients who are ultimately progressing toward end-stage renal disease care to preserve their veins for arteriovenous distally.” -- Dr. Glenn Chowtow - Chief, Division of Nephrology and Professor of Medicine at Stanford University School of Medicine, 11/5/13 conference call.

Need anymore info?

Another Yahoo boardie. Only someone who doesn't work for Keryx would post this and even care.

 

[anonymous]

I don't even work for the company but I can tell you...

Auryxia ...

1. Is an effective phosphate binder

2. Increased ferritin (Renvela/Phoslo +2% … Auryxia + 51% (p=.0001))

3. Increased TSAT (Renvela/Phoslo -3% … Auryxia + 26% (p=.0001))

4. Lowers Iron-IVs (= $hundreds of millions saved / year)

5. Lowers ESA’s (= $hundreds of millions saved / year)

6. Causes higher hemoglobin (Renvela/Phoslo -0.6(g/dL … Auryxia +0.2 g/dL (p = .0105)

7. Causes lower FGF-23 (Placebo +11% … Auryxia -37% (p = .017)

8. Has fewer serious side effects

9. Results in 24% fewer hospitalizations (!) (= $thousands saved per member per year, not to mention what this means to patients)

10. Saves veins – “I think another important point for those patients with CKD who eventually progress is simply avoiding intravenous cannulations and hospitalizations and infusion center admissions are not only cost savings but they are vein savings. Meaning that avoiding intravenous therapy of any type is a priority for patients who are ultimately progressing toward end-stage renal disease care to preserve their veins for arteriovenous distally.” -- Dr. Glenn Chowtow - Chief, Division of Nephrology and Professor of Medicine at Stanford University School of Medicine, 11/5/13 conference call.

Need anymore info?

Lets see all of the above statements have led to

a 1% market share 1.5 years post launch
a crashing of the stock price
potential share holder lawsuits
significant drain of cash on hand
multiple investigations from external agencies regarding marketing practices
firing of VP sales (guy was a mess anyway)
CEO about to be fired
missed revenues for every Quarter since launch (may have hit one not sure)

Your marketing messages above are truly brilliant. Lets promote the fact your have a warning in your label as an advantage and primary marketing message!?!?! How in the world your whole Marketing and Medical Team and CCO did all not get axed is beyond belief!!!!

 

[anonymous]

Finally someone who knows what they are talking about. Well said my friend...its spelled DOG

 

[anonymous]

Finally someone who knows what they are talking about. Well said my friend...its spelled DOG

It's such a dog that Princeton One is literally stalking potential candidates.... Regional Directors "won't comment" on % to goal to potential candidates, yet they talk about what a small, nimble, transparent company and culture it is.

 

[anonymous]

Transparent? Is that what they're saying? Thats funny

It's such a dog that Princeton One is literally stalking potential candidates.... Regional Directors "won't comment" on % to goal to potential candidates, yet they talk about what a small, nimble, transparent company and culture it is.

 

[anonymous]

Did Tony graduate from UMASS? Must have if Greggo hired him.

Hated at Cubist , will be hated at Keryx